This study focuses on Primary Aldosteronism, a condition where the body produces too much of a hormone called aldosterone. The study will test a medication called Baxdrostat (also known as CIN-107) to see how well it works and how safe it is for treating this condition. Primary Aldosteronism can cause high blood pressure and changes in blood potassium levels.
The study will compare Baxdrostat tablets with placebo in adults who have Primary Aldosteronism. During the study, participants will take either Baxdrostat or placebo orally each day. The medication dose may range from 2 to 4 milligrams per day. The main purpose is to determine if Baxdrostat can help lower blood pressure in people with this condition.
The treatment period will last for about one year (52 weeks). Throughout the study, participants will have their blood pressure monitored, and doctors will check various health measurements including hormone levels in blood and urine. The study will also track how the medication affects potassium levels in the blood.
France 
Germany 
Italy 
Spain 